The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the common ingredient phenylephrine off ...

The U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph ...

demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial ...

Citing topline data from their Phase 3 WAYPOINT trial, the companies said that the antibody therapy reduced the size of nasal ...

This follows an extensive review that found the drug ineffective for treating nasal congestion. Oral phenylephrine, widely ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...

If you are unfortunate enough to come down with sickness, Doctor Sooj said: “Stay well hydrated, as this can soothe your ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.